Moreover, by genotyping 713 patients on statin therapy, the presence of a polymorphism of the DMPK (rs672348) gene, which encodes a protein kinase implicated in myotonic dystrophy, as well as COQ2 (rs4693570) encoding para-hydroxybenzoate-polyprenyltransferase, which participates in the biosynthesis of coenzyme Q10 (p < 0.000041) and ATP2B1 (rs17381194) which encodes calcium transporting ATPase were all significantly linked to the development of muscular side effects [131]. The gene discussed is COQ2; the disease is myotonic dystrophy.